Skip to main content
. Author manuscript; available in PMC: 2013 Nov 7.
Published in final edited form as: J Clin Oncol. 2004 Nov 1;22(21):10.1200/JCO.2004.09.096. doi: 10.1200/JCO.2004.09.096

Table 2.

Toxicities Noted During Fenretinide Therapy Reported As Related to the Treatment

Toxicity Grade 1 Grade 2 Grade 5
Abdominal pain 2 0 0
Abdominal cramping 1 0 0
Alopecia 1 0 0
Amylase increase 1 0 0
Anemia 4 0 0
Bleeding (without grade 3 or 4 thrombocytopenia) 0 0 1
CNS bleeding* 0 0 0
Cognitive disturbance 2 0 0
Confusion 0 2 0
Constipation 1 0 0
Diarrhea 3 1 0
Dizziness 4 0 0
Dry skin 3 1 0
Edema 1 0 0
Elevated transaminases 2 0 0
Elevated lactate dehydrogenase 1 0 0
Erythema multiforme 0 1 0
Fatigue 8 3 0
Headache 3 0 0
Hypercholesterolemia 2 0 0
Hypertriglyceridemia 1 0 0
Hypoalbuminemia 3 0 0
Hypokalemia 1 0 0
Hyponatremia 1 0 0
Hypophosphatemia 0 1 0
Infection without neutropenia 0 1 0
Insomnia 2 0 0
Leukopenia 3 0 0
Lymphocytopenia 1 1 0
Muscle weakness 0 1 0
Nausea or vomiting 2 1 0
Night blindness 1 0 0
Photoposia 1 0 0
Pruritus 1 0 0
Seizures 0 1 0
Skin rash 2 1 0
Speech impairment 0 1 0
Stomatitis 1 0 0
Thrombocytopenia 3 0 0
Watery eyes 2 0 0
Xerostomia 3 0 0
Total 67 16 1
*

Grade 3 and grade 4 CNS hemorrhage (intratumoral bleeding) was noted in one patient each.

One patient had grade 3 nausea.